|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bourreille J, Metayer P, Sauger F, Matray
F and Fondimare A: Existence of alpha fetoprotein during
gastric-origin secondary cancer of the liver. Presse Med.
78:1277–1278. 1970.(In French). PubMed/NCBI
|
|
3
|
Hirajima S, Komatsu S, Ichikawa D, Kubota
T, Okamoto K, Shiozaki A, Fujiwara H, Konishi H, Ikoma H and Otsuji
E: Liver metastasis is the only independent prognostic factor in
AFP-producing gastric cancer. World J Gastroenterol. 19:6055–6061.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kono K, Amemiya H, Sekikawa T, Iizuka H,
Takahashi A, Fujii H and Matsumoto Y: Clinicopathologic features of
gastric cancers producing alpha-fetoprotein. Dig Surg. 19:359–365.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang YC, Nagasue N, Kohno H, Taniura H,
Uchida M, Yamanoi A, Kimoto T and Nakamura T: Clinicopathologic
features and long-term results of alpha-fetoprotein-producing
gastric cancer. Am J Gastroenterol. 85:1480–1485. 1990.PubMed/NCBI
|
|
6
|
Chun H and Kwon SJ: Clinicopathological
characteristics of alpha-fetoprotein-producing gastric cancer. J
Gastric Cancer. 11:23–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long
Z, Zhu H and Wang Y: Clinicopathologic features and prognostic
factors in alpha-fetoprotein-producing gastric cancers: Analysis of
104 cases. J Surg Oncol. 102:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McIntire KR, Waldmann TA, Moertel CG and
Go VL: Serum alpha-fetoprotein in patients with neoplasms of the
gastrointestinal tract. Cancer Res. 35:991–996. 1975.PubMed/NCBI
|
|
9
|
Lauren P: The two histological main types
of gastric carcinoma: diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
|
|
10
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed.
June 16–2014
|
|
11
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koneri K, Hirono Y, Fujimoto D, Sawai K,
Morikawa M, Murakami M, Goi T, Iida A, Katayama K and Yamaguchi A:
Five-year survival of alpha-fetoprotein producing gastric cancer
with synchronous liver metastasis: A case report. J Gastric Cancer.
13:58–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lew DH, Jung WT, Kim HJ, Min HJ, Ha CY,
Kim HJ, Kim TH and Ko GH: Clinicopathological characteristics and
prognosis of alpha-fetoprotein producing gastric cancer. Korean J
Gastroenterol. 62:327–335. 2013.(In Korean). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamaguchi K, Tada M, Horikoshi N, Otani T,
Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y, et
al: Phase II study of paclitaxel with 3-h infusion in patients with
advanced gastric cancer. Gastric Cancer. 5:90–95. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Emi Y, Yamamoto M, Takahashi I, Orita H,
Kakeji Y, Kohnoe S and Maehara Y: Phase II study of weekly
paclitaxel by one-hour infusion for advanced gastric cancer. Surg
Today. 38:1013–1020. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Narahara H, Iishi H, Imamura H, Tsuburaya
A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C and Sakata Y:
Randomized phase III study comparing the efficacy and safety of
irinotecan plus S-1 with S-1 alone as first-line treatment for
advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer.
14:72–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ajani JA, Rodriguez W, Bodoky G,
Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A,
Lang I and Falcon S: Multicenter phase III comparison of
cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced
gastric or gastroesophageal adenocarcinoma study: The FLAGS trial.
J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fukuda K, Ito S, Shimizu K, Mikami E,
Sakuraba S, Shiroki T, Ikehata A, Murakami A, Ono S, Sakuma T and
Kato S: Retrospective analysis concerning AFP-producing gastric
cancer. Gan To Kagaku Ryoho. 40:191–195. 2013.(In Japanese).
PubMed/NCBI
|
|
19
|
Shiochi H, Yamada M, Kishina M, Murawaki
Y, Miura M, Azumi T, Yuuki T, Tanaka S, Kono M, Yoshimura T, et al:
A case of AFP-producing gastric cancer responding to the
combination of systemic chemotherapy, transcatheter arterial
embolization and hepatic infusion chemotherapy. Gan To Kagaku
Ryoho. 36:843–846. 2009.(In Japanese). PubMed/NCBI
|
|
20
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S,
Kim JS, Yang TS, Tak WY, Pan H, Yu S, et al: Efficacy and safety of
sorafenib in patients with advanced hepatocellular carcinoma
according to baseline status: Subset analyses of the phase III
Sorafenib Asia-Pacific trial. Eur J Cancer. 48:1452–1465. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim C, Lee JL, Choi YH, Kang BW, Ryu MH,
Chang HM, Kim TW and Kang YK: Phase I dose-finding study of
sorafenib in combination with capecitabine and cisplatin as a
first-line treatment in patients with advanced gastric cancer.
Invest New Drugs. 30:306–315. 2012. View Article : Google Scholar : PubMed/NCBI
|
